Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography
Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography
复制标题
DOI：
10.1002/cncr.10599
复制
发表时间：
2002-06-15
期刊：
影响因子：
6.2
通讯作者：
Eary, JF
中科院分区：
文献类型：
--
作者：
Hawkins, DS;Rajendran, JG;Eary, JF
背景对新辅助化疗的反应是骨肉瘤（OS）和尤文肉瘤家族肿瘤（ESFT）的重要预后因素。传统的放射学成像不能区分有反应和无反应的骨肿瘤。[F-18]-氟脱氧-D-葡萄糖（FDG）正电子发射断层扫描（PET）是一种非侵入性成像方式，可准确预测各种恶性肿瘤患者的组织病理学反应。为了描述FDG PET成像的特点，并确定FDG PET成像与骨肉瘤儿童化疗反应之间的相关性，我们回顾了我们的单一机构的经验。通过FDG PET评价了33例原发部位为骨性的OS或ESFT儿科患者。所有患者均接受标准新辅助化疗。分析化疗前（SUV 1）和化疗后（SUV 2）的FDG PET标准摄取值，并与手术切除肿瘤的组织病理学评估的化疗反应相关。26例患者有SUV 1、SUV 2和手术切除。虽然OS或ESFT儿童的平均SUV 1相似（8.2。与5.3相比，P = 0.13），OS患者的平均SUV 2大于ESFT患者的值（3.3与1.5，P = 0.01）。所有ESFT患者和28%的OS患者对化疗有良好的组织学反应（大于或等于90%坏死）。合并ESFT和OS患者，SUV 2和SUV 2与SUV 1的比值（SUV 2：SUV 1）与组织学反应相关（两种比较P = 0.01）。儿童骨肉瘤的FDG PET评估显示新辅助化疗的反应有显著变化。suv 2和suv 2：SUV 1与组织病理学评估的反应，并可能被用作一个非侵入性的替代，以预测患者的反应。(C)2002年美国癌症协会。
BACKGROUND. Response to neoadjuvant chemotherapy is a significant prognostic factor for osteosarcoma (OS) and the Ewing sarcoma family of tumors (ESFT). Conventional radiographic imaging does not discriminate between responding and nonresponding osseous tumors. [F-18]-fluorodeoxy-D-glucose (FDG) positron emission tomography (PET) is a noninvasive imaging modality that accurately predicts histopathologic response in patients with various malignancies. To describe the FDG PET imaging characteristics and to determine the correlation between FDG PET imaging and chemotherapy response in children with bone sarcomas, we reviewed our single institution experience.METHODS. Thirty-three pediatric patients with OS or ESFT with osseous primary sites were evaluated by FDG PET. All patients received standard neoadjuvant chemotherapy. FDG PET standard uptake values before (SUV1) and after (SUV2) chemotherapy were analyzed and correlated with chemotherapy response assessed by histopathology in surgically excised tumors. Twenty-six patients had SUV1, SUV2, and surgical excision.RESULTS. Although the mean SUV1 in children with OS or ESFT were similar (8.2. vs. 5.3, P = 0.13), mean SUV2 for OS patients was greater than the values for ESFT patients (3.3 vs. 1.5, P = 0.01). All ESFT patients and 28% of OS patients had a favorable histologic response to chemotherapy (greater than or equal to 90% necrosis). Combining ESFT and OS patients, both SUV2 and the ratio of SUV2 to SUV1 (SUV2:SUV1) were correlated with histologic response (P = 0.01 for both comparisons).CONCLUSION. FDG PET evaluation of pediatric bone sarcomas demonstrated significant alteration in response to neoadjuvant chemotherapy. SUV2 and SUV2: SUV1 correlated with histopathologic assessment of response and potentially could be used as a noninvasive surrogate to predict response in patients. (C) 2002 American Cancer Society.